![Page 1: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/1.jpg)
PulmonaryHypertensionin2017
CatherineFallick,MD,FACCDirector,PulmonaryHypertension
MetroHealthMedicalCenterAssistantProfessor,CWRU
![Page 2: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/2.jpg)
NodisclosuresNooff-labelusesofmedicaCons
![Page 3: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/3.jpg)
Introduc8on
• 1.DefiniConandpathophysiologyofpulmonaryarterialhypertension
• 2.PrevalenceandprognosisofPAH
• 3.Diagnosisofpulmonaryarterialhypertension
• 4.Nonpharmacologictreatmentofpulmonaryarterialhypertension
![Page 4: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/4.jpg)
• 1.DefiniConandpathophysiologyofpulmonaryarterialhypertension
• 2.PrevalenceandprognosisofPAH
• .Diagnosisofpulmonaryarterialhypertension
• 3.Nonpharmacologictreatmentofpulmonaryarterialhypertension
![Page 5: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/5.jpg)
Pulmonary arterial hypertension (PAH) is a syndrome
resulting from restricted flow through the pulmonary arterial
circulation resulting in increased pulmonary vascular
resistance and ultimately in right heart failure and death. Multiple
pathogenic pathways have been implicated in the development
of PAH. The imbalance in the vasoconstrictor/vasodilator
milieu has served as the basis for current medical therapies,
although increasingly it is recognized that PAH also involves
an imbalance of proliferation and apoptosis (favoring
the former).
Defini8onofPAH
![Page 6: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/6.jpg)
Panvasculopathy (endothelium dysfunction, medial hypertrophy and adventitial proliferation)""Predominant effect on resistance arteries""Thrombosis in situ""Inflammation""Plexiform lesions""
![Page 7: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/7.jpg)
JACC Vol. 53, No. 17, 2009 April 28, 2009:1573–619"Expert Consensus Document on Pulmonary Hypertension"
![Page 8: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/8.jpg)
Evolu8onofPAH:Mul8plesuspects!
• Atsmoothmusclecelllevel:– RiseinintracellularcalciumduetomulCplemechanisms(such
asinac*va*onofKvchannelsand/orOverexpressionofCa++channels),resulCngin:
• ContracCon/vasoconstricCon• ProliferaCon
– DysfuncConofBoneMorphogenicProteinreceptor(suchasinBMPRmuta*ons)resulCngin:
• IncreasedproliferaCon• Reducedapoptosis
• AtEndothelialcelllevel:– ReducedNitricoxideandprostacyclinproducConresulCngin
• SustainedvasoconstricCon• IncreasedinflammaCon
– DysfuncConinBMPreceptor(suchasinBMPRmuta*ons)resulCngin
• IncreasedAngiopoieCnproducConandincreasedproliferaConandangiogenesis.
– Over-expressionofEndothelinreceptors(notinthefigure)resulCngin
• VasoconstricCon• IncreasedinflammaCon
Yuan JX et al. Circulation 2005"
![Page 9: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/9.jpg)
Introduc8on
• 1.DefiniConandpathophysiologyofpulmonaryarterialhypertension
• 2.PrevalenceandprognosisofPAH
• .Diagnosisofpulmonaryarterialhypertension
• 3.Nonpharmacologictreatmentofpulmonaryarterialhypertension
![Page 10: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/10.jpg)
EpidemiologyofPH:
• Prevalence:– iPAHandheritablePHarerare:5-15permillion– PAH-HIV:lessthan1%ofHIVpaCents)– PAH-ACHD:increasinglyseenaspopulaConwithACHDisrapidlyincreasing.– PAH-CTD:5-12%ofpaCentswithSystemicSclerosis(SSc)andCRESTsyndrome.RareinotherCTD(SLE,mixed
CTD,RA,dermatomyosiCs,andSjo¨gren’ssyndrome)– PoPAH:1-5%ofpaCentswithportalhypertension(withorwithoutcirrhosis)– PVOD:Extremelyrare.Obenassociatedwithpulmonaryhemangiomatosis– WHOgroup2PH:ItisesCmatedtoinvolve70-90%ofpaCentslebHF– WHOgroup3,4,and5:Prevalenceunknown.
• MostcommoninUS:PH-LHD• Mostcommonworldwide:schistosomiasis-associatedPHandhighalCtudePH
Nazzarino Galie et al. European Heart Journal 2015"Redfield MM et al. JACC 2009"
![Page 11: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/11.jpg)
Familial PAH
– 6-10%ofIPAHpaCents– MutaConsinBMPR-2,ALK-1geneswhichbelongtotheTGFβsuperfamilyofgrowthfactors
– Two-thirdsofFPAHpaCentshaveBMPR-2mutaCon– ALK-1mutaConassociatedwithHHT(Osler-Weber-Rendudisease)
– PresenceofBMPR-2mutaConconfersa10-20%riskofdevelopingPAH
![Page 12: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/12.jpg)
Prevalence of PAH Associated with SSc
0
5
10
15
20
25
30
Prevalence
New PHTotal PH
• “UNCOVER” study • Point prevalence of PAH in
50 • community clinics • Pts with SSc or MCTD
without • known PAH screened with • ECHO, PFT • 89/669 (13.3%) had RVSP
>40 • mm Hg. • Total prevalence was 89
(new) • + 122 (known) = 211/791 • (26.7%) “New” PAH found in 13% of patients with SSc, MCTD
![Page 13: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/13.jpg)
SurvivalinSclerodermaPa8entsWithPAH,LungInvolvement,orNoMajorOrganInvolvement
Koh ET et al. Br J Rheumatol. 1996;35:989-993.
Survival %
0
20
40
60
80
100
0 1 2 3 4 5 6 7 8 9 10 11 12 13 Years from diagnosis of PH
PAH
Lung involvement (without PAH)
None
Copyright Case/UHHS CME 2005 All Rights Reserved
![Page 14: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/14.jpg)
PAH-CongenitalHeartDisease
• Left to Right Shunts • ASD • VSD • PDA • Surgical Shunts
Complex Lesions • DORV • Truncus Arteriosus
• TGV/VSD
![Page 15: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/15.jpg)
Survival in Eisenmenger’s Syndrome
20
1 – –
0.8 – –
0.6 – –
0.4 – –
0.2 – –
0 –
Survival
Age (years)
Vongpatanasin et al. Ann Intern Med. 1998; 128: 745-755.
30 40 50 60 70
Patients (n) 78 40 13 4
n = 109
Mean age of death 45 yrs
20 % die during a medical procedure or ill advised activity
![Page 16: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/16.jpg)
Classifica8onofPHbasedone8ology:
Nazzarino Galie et al. European Heart Journal 2015"
![Page 17: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/17.jpg)
Familial PAH
– 6-10%ofIPAHpaCents– MutaConsinBMPR-2,ALK-1geneswhichbelongtotheTGFβsuperfamilyofgrowthfactors
– Two-thirdsofFPAHpaCentshaveBMPR-2mutaCon– ALK-1mutaConassociatedwithHHT(Osler-Weber-Rendudisease)
– PresenceofBMPR-2mutaConconfersa10-20%riskofdevelopingPAH
![Page 18: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/18.jpg)
Introduc8on
• 1.DefiniConandpathophysiologyofpulmonaryarterialhypertension
• 2.PrevalenceandprognosisofPAH
• 3.Diagnosisofpulmonaryarterialhypertension
• 4.Nonpharmacologictreatmentofpulmonaryarterialhypertension
![Page 19: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/19.jpg)
DiagnosCctestsforevaluaCngpaCentswithpulmonaryhypertension
• Toestablishdiagnosis:– Echocardiogram– RightheartcatheterizaCon
• Todetermineprognosisandresponsetotherapy– 6MWD– CardiopulmonaryexercisetesCng– LaboratorytesCng:BNP,NT-Pro-BNP,Troponin– CardiacMRI:AssessRVfuncCon
• TodetermineeCology– VenClaCon/perfusionscan/CTA/pulmonaryangiogram– PulmonaryfuncContesCng– HighresoluConCTscan– Bronchoscopy/Lungbiopsy– HepaCcultrasound– MRI:ACHD,ruleoutCTEPHinpregnancy,evaluateRV– LaboratorytesCng:HIVserology,Auto-immunetesCng,hepaCCsserology,thrombophiliaworkup– GeneCctesCng
![Page 20: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/20.jpg)
Clinical Signs of PH:
• Presence of PH – Loud P2 – RV lift – Systolic murmur (TR) – Diastolic murmur (PR) – RV S4
• Presence of RV failure – JVD, V wave – RV S3 – Hepatomegaly – Edema – Ascites
![Page 21: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/21.jpg)
PH: Diagnostic Approach
Symptoms / Physical Exam Screening Procedures PH Suspicion
Incidental Findings ECG
PH Detection Chest Radiograph
Echocardiogram
Pulmonary Function, oxygenation
PH Characterization
Exercise Capacity Hemodynamics
Adapted from: ESC Guidelines. Eur Heart J 2004; 25:2243
6 Min Walk Test, peak VO2 Right Heart Cath + Vasoreactivity
Ventilation Perfusion Scan CT angio and HRCT Pulmonary angiogram Serology, LFT, HIV,
![Page 22: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/22.jpg)
RVH
RV Strain
RAD
RAE
EKG in PH:
In IPAH, RAD seen in 79%, and RVH in 87%. EKG as a screening tool for IPAH: sensitivity 55%, specificity 70%.
![Page 23: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/23.jpg)
RV"
RA"RA"
LA"
LV"
![Page 24: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/24.jpg)
![Page 25: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/25.jpg)
Pulmonary Arterial Hypertension: Diagnosis
• Establish presence and severity
• Echo • Cath • ? MRI or CT angio
• EstablisheCology• Blood Work to r/o CTD, HIV, • SSD, CLD • PFT/CT/X-ray to r/o lung • disease • VQ/ CT/PA angiogram to r/o • CTEPH • Sleep study • TTE/TEE/Cath/MRI to r/o • heart disease
3"
![Page 26: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/26.jpg)
Hemodynamicdefini8onandclassifica8onofPH
Nazzarino Galie et al. European Heart Journal 2015"
![Page 27: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/27.jpg)
whyisitimportanttodeterminecauseofpulmonaryhypertension?
• PaCentswithpulmonaryarteryhypertensionneedtreatment,andneeditbeforetherightventriclebeginstofail.
• PaCentswithnonGroup1diseasecanbetreatedthroughCtraConofmedicaConsforGroup2andpossiblyevaluaConforadvancedtherapies,evaluaConofpulmonarydiseaseforGroup3paCents,treatmentofpulmonaryemboli(medicalvssurgical)forGroup4paCents,andappropriateunusualdiagnosescanbemadeforGroup5paCents.
![Page 28: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/28.jpg)
Hemodynamic Progression of PAH
Pre-symptomatic/ Compensated
Symptomatic/ Decompensating
Declining/ Decompensated
Symptom Threshold
Right Heart Failure
CO
RAP
TPG= PAP-PAW PVR=TPG/ CO
![Page 29: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/29.jpg)
Predictorsofpoorprognosis
• 6minutewalk<300meters• Presenceofapericardialeffusion• RApressure>20mmhg• WHOclassIVsymptomsorsyncope• ElevatedBNP
![Page 30: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/30.jpg)
RiskassessmentinPAH
Nazzarino Galie et al. European Heart Journal 2015"
![Page 31: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/31.jpg)
PHCC,MetrohealthMedicalCenter
• Cardiologyrunwithpulmonarylead• DirectreferralfromPCPorthroughPulmonary,generalcardiology,orheartfailurecardiology
• Referralfromecholab• ReferralfrominpaCentconsults.
![Page 32: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/32.jpg)
RightHeartCatheterizaConandVaso-reacCvitystudy
• RHCisrecommendedwhen:– Group1PAHissuspected– Group2,withLVfailureisbeingconsideredforHT– WhenPAHtherapyisbeingconsidered– ForfollowuptodetermineresponsetoPAHtherapy
• Vaso-reacCvitystudyisrecommendedwhen:– PAHissuspected(PCWP<15)
• LHCforLVEDPwhen:– PCWPcouldnotbeobtainedorconfirmed– PCWPreadingisnotconsistentwiththeclinicalpicture
• Shuntrunisrecommendedwhen:– SuspecCngL-Rshuntbyotherimagingorbyhistory– PAO2sat>75%
Nazzarino Galie et al. European Heart Journal 2015"
![Page 33: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/33.jpg)
![Page 34: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/34.jpg)
Months 0
0
20
Surv
ival
(%)
40
60
80
100
12 36 24 48 60
Response / Warfarin
No Response / Warfarin
Response / No Warfarin
No Response / No Warfarin
Survival in IPAH with CCB and Anticoagulation Therapy
Rich et al. NEJM 1992;327:76–81 Copyright Case/UHHS CME 2006 All Rights Reserved
64 pts"
Avg dilt dose 720 mg "Avg nifedipine dose 175 mgmg"
![Page 35: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/35.jpg)
SurvivalCurveaSer12weeksEpoprostenol Therapy
Barst, NEJM 1996 Feb 1;334(5):296-302. "
![Page 36: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/36.jpg)
Long-TermOutcomeinIPAHWithEpoprostenol
Sitbon O et al. J Am Coll Cardiol. 2002;40:780-788.
No. at risk 178 129 85 57 36 21 7 3 1 IV epo 135 59 34 20 11 4 2 2 1 Hist. control
1 C
umul
ativ
e su
rviv
al
Months
0.8
0.6
0.4
0.2
0
IV epoprostenol (n=178)
Historical control (n=135)
0 12 24 36 48 60 72 84 96 108 120
Months
McLaughlin VV et al. Circulation. 2002;106:1477-1482.
Expected
Observed (n=162)
*
*
*
20
40
60
80
100
% S
urvi
val
0 6 12 18 24 30 36
*p<0.001
p<0.0001
Copyright Case/UHHS CME 2006 All Rights Reserved
![Page 37: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/37.jpg)
![Page 38: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/38.jpg)
• 1.DefiniConandpathophysiologyofpulmonaryarterialhypertension
• 2.PrevalenceandprognosisofPAH
• 3.Diagnosisofpulmonaryarterialhypertension
• 4.Nonpharmacologictreatmentofpulmonaryarterialhypertension
![Page 39: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/39.jpg)
Balloonatrialseptostomy
• RecommendedaspalliaCvetherapyorbridgetolungtransplantin:– FuncConalclassIVpaCentsfailingmedicaltherapy– RVfailuredespitemaximummedicaltherapy– Recurrentsyncopeduetoseverelylowcardiacoutput.
• Contraindicatedif:– RAP>20mmHg– ArterialO2saturaCon<85%
Nazzarino Galie et al. European Heart Journal 2015"
![Page 40: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/40.jpg)
Otheradvancedop8onsinsevereRVfailure:
• Inotropicsupport(temporaryorhomeinfusion)• ECMOasabridgetolungtransplant• RVADisNOTanopConduetohighaberload• Lungtransplant
![Page 41: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/41.jpg)
Treatmentofpulmonaryhypertension
• OpCmalmanagementoflebsidedheartfailure• OpCmalmanagementofsleepdisorderedbreathing(OSA)• EndarterectomyinselectedpaCentswithchronicpulmonaryemboli• Oxygentherapy
![Page 42: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/42.jpg)
Thankyou!
![Page 43: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/43.jpg)
Recommenda8onsforgeneralmeasures
Nazzarino Galie et al. European Heart Journal 2015"
![Page 44: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/44.jpg)
Recommenda8onsforsuppor8vetherapy
Nazzarino Galie et al. European Heart Journal 2015"
![Page 45: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/45.jpg)
PAH-specificdrugs:Mono-therapy
Nazzarino Galie et al. European Heart Journal 2015"
![Page 46: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/46.jpg)
Combina8ontherapy
Nazzarino Galie et al. European Heart Journal 2015"
![Page 47: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/47.jpg)
PAH-specificdrugs:SequenCaltherapy
Nazzarino Galie et al. European Heart Journal 2015"
![Page 48: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/48.jpg)
ManagementofPAH-ACHD
• ExcludePHsecondarytoLVdysfuncConorassociatedlungdisease.• StartPAHmedicaConsearly• ClosureofL-Rshuntifindicated• Othermanagementaspects:
– Oxygen,hydraCon– AnCcoagulaConinabsenceofhemoptysis– AvoidCa++blockers– IVfilterstopreventparadoxicalemboli
Nazzarino Galie et al. European Heart Journal 2015"
![Page 49: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/49.jpg)
PAHassociatedwithconnecCveCssuedisease(PAH-CTD)
• ScreeningasymptomaCcpaCentsisrecommendedinSScwithannualechocardiogram,DLCOandbiomarkers.
• Evaluateforgroup2(duetodiastolicdysfuncCon)andgroup3(duetoILD)
• StartPAHmedicaConsearly
Nazzarino Galie et al. European Heart Journal 2015"
![Page 50: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/50.jpg)
PAHassociatedwithportalhypertension(PoPH)
• PaCentstendtohavehigherCIandlowerPVR• ScreeningforPoPAHisrecommendedpriortolisCngforlivertransplant.• Associatedwithhighmortalitypostlivertransplant:
– 100%formPAP>50– 50%formPAP35-50mmHg
• SupporCvemeasures:– AvoidanCcoagulaCon– Avoidbetablockers(obenusedforEvarices)– AvoidERAs,especiallyBosentan
Nazzarino Galie et al. European Heart Journal 2015"
![Page 51: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/51.jpg)
PAHassociatedwithHIVinfecCon:
• ScreeningasymptomaCcpaCentsisnotrecommendedduetolowincidence.
• Ruleout– PoPAH– drug-inducedPAH– group2(duetoLHD)– group3(ILD)– group4(CTEPH)
• BeawareofinteracConbetweenERAandHIVmedicaCons
Nazzarino Galie et al. European Heart Journal 2015"
![Page 52: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/52.jpg)
PVOD/PCH
• Veryrare• Suspectwhen:
– Chronicpulmonaryedemawithhypoxia,clubbing,DOE– HemodynamicsconsistentwithPAH,butwithhighPCWP– SeverereducConinDLCO– CharacterisCcfindingsonHRCT:
• Sub-pleuralthickenedseptallines• ground-glassopaciCes• mediasCnallymphadenopathy• occultalveolarhemorrhageonBronchoscopy• ExaggeratedriseinPCWPduringreversibilitystudy
• Goldstandardislungbiopsybutobennotnecessary• Therapy:
– DiureCcs,Oxygen– SlowintroducConofPAHmedicaCons(obennottolerated)– ExperimentaluseofangiogenesisinhibitorssuchasINFalpha2– Lungtransplant
Nazzarino Galie et al. European Heart Journal 2015"
![Page 53: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/53.jpg)
PH-LHD(group2PH)
• TreatunderlyingLVdysfuncConorvalvulardisease• PDE-5inhibitorshavebeenusedinpaCentsawaiCngHTandresultedinreducConofPVR
• OngoingtrialsfortheuseofPDE-5andERAinthesepaCents.– Sildenafil:SilHF(NCT01616381)– Macitentan:Melody-1(NCT02070991)
![Page 54: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/54.jpg)
PHduetolungdiseaseand/orhypoxia(Group3PH)
• MostcommonlyseeninCOPD,ILD,IPF.• RarelyseeninOSAwithoutlebheartdisease• Usuallymildtomoderate.Ifsevere,lookforothercauses• NocorrelaConbetweenseverityoflungdiseaseandseverityofPH• Mechanismisthoughttobehypoxia-inducedchronicvasoconstricCon• O2therapycanslowdownprogressionofdisease• PAHmedicaConsarenotrecommendedunlessmixedeCology(groups1,3)is
suspected(asinscleroderma• VasodilatorsandPAHmeds,ifused,mayworsenhypoxia
Nazzarino Galie et al. European Heart Journal 2015"
![Page 55: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/55.jpg)
ChronicthromboembolicPH(CTPH)Group4PH
• MajorityarediagnosedinpaCentwithnopriorclinicalhistoryofPE• LifelonganCcoagulaCon• Alwaysassesscandidacyforpulmonaryendarterectomy• StartPAHmedicaConsearlyonevenabersurgeryifPHdoesnotresolve
Nazzarino Galie et al. European Heart Journal 2015"
![Page 56: Pulmonary Hypertension in 2017 - Ohio-ACCPulmonary arterial hypertension (PAH) is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in](https://reader033.vdocument.in/reader033/viewer/2022041913/5e6855dc021fec61e2112324/html5/thumbnails/56.jpg)
PHduetounclearand/ormulCfactorialmechanismsGroup5PH
• Heterogeneousgroupwithpoorlyunderstoodmechanismsincluding:– pulmonaryvasoconstricCon– proliferaCvevasculopathy– extrinsiccompression(Histoplasmosis/fibrosingmediasCniCs,hydatedcysts)– intrinsicocclusion(PVstenosisaberPVI)– high-outputcardiacfailure(chronicanemiaespeciallyhemolyCcanemia,AV-shunts)
• TreatmentistargeCngtheunderlyingcauseNazzarino Galie et al. European Heart Journal 2015"